The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis
- 30 November 2008
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 62 (2), 242-252
- https://doi.org/10.1016/j.lungcan.2008.03.001
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals Of Oncology, 2006
- Where next for gefitinib in patients with lung cancer?The Lancet Oncology, 2006
- A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancerCurrent Medical Research and Opinion, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving GefitinibThe Cancer Journal, 2005
- Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung CancerInternal Medicine, 2005
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviewsBMJ, 1998
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995